Navigating 9 Analyst Ratings For United Therapeutics
Portfolio Pulse from Benzinga Insights
United Therapeutics (NASDAQ: UTHR) received mixed analyst ratings over the last quarter, with a majority being bullish. The average 12-month price target increased to $336.78, with a high of $400.00 and a low of $240.00. The company showed strong financial performance with significant revenue growth, high net margins, and effective debt management.
July 25, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
United Therapeutics received a mix of bullish and somewhat bullish ratings from analysts, with an average 12-month price target of $336.78. The company's strong financial performance, including a 33.7% revenue growth rate and high net margins, supports a positive outlook.
The majority of analysts have a bullish outlook on UTHR, with several raising their price targets. The company's strong financial metrics, including high revenue growth and net margins, support a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100